Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

Author:

Tan Lih Yin12,Martini Carmela12,Fridlender Zvi G3,Bonder Claudine S1,Brown Michael P145,Ebert Lisa M1

Affiliation:

1. Centre for Cancer Biology, University of South Australia and SA Pathology; Adelaide SA Australia

2. School of Pharmacy and Medical Sciences, University of South Australia; Adelaide SA Australia

3. Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center; Jerusalem Israel

4. Cancer Clinical Trials Unit, Royal Adelaide Hospital; Adelaide SA Australia

5. Discipline of Medicine, University of Adelaide; Adelaide SA Australia

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Reference100 articles.

1. Neoantigens in cancer immunotherapy;Schumacher;Science,2015

2. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?;Welsh;Eur J Cancer,2016

3. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian Suzanne;Cancer Cell,2015

4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

5. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort;Long;J Clin Oncol,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3